Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Risk factors

Topic: Risk, prevention and care in population studies

Plain-language summary

The aging population is increasingly affected by both diabetes mellitus and hearing loss, two conditions that often coexist and can significantly impact quality of life. As the prevalence of diabetes rises with age, so does the incidence of hearing impairment, with both conditions contributing to cognitive decline and functional limitations. The interplay between diabetes, hearing loss, and cognition highlights the need for comprehensive healthcare strategies that address the unique challenges faced by older adults. This review explores the mechanisms underlying the interplay between these three conditions, including mitochondrial dysfunction, neuroinflammation, oxidative stress, and microangiopathy.

What this study adds

Evidence grade: Low

This review discusses how diabetes and hearing loss may coexist and contribute to cognitive decline, exploring mechanisms such as mitochondrial dysfunction, neuroinflammation, oxidative stress and microangiopathy. It presents no new treatment or prevention trial results and does not test whether treating either condition reduces dementia risk.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Waissbluth, S., & Delano, P. H. (2025). Dissecting the Interactions of Diabetes Mellitus and Hearing Loss with Cognitive Decline and Dementia. Brain Sciences. https://doi.org/10.3390/brainsci15070669

Vancouver

Waissbluth S, Delano PH. Dissecting the Interactions of Diabetes Mellitus and Hearing Loss with Cognitive Decline and Dementia. Brain Sciences. 2025. doi:10.3390/brainsci15070669. PMID: 40722262.

BibTeX

@article{waissbluth2025-40722262,
  author  = {Waissbluth, Sofia and Delano, Paul Hinckley},
  title   = {{Dissecting the Interactions of Diabetes Mellitus and Hearing Loss with Cognitive Decline and Dementia}},
  journal = {Brain Sciences},
  year    = {2025},
  doi     = {10.3390/brainsci15070669},
  pmid    = {40722262},
  url     = {https://doi.org/10.3390/brainsci15070669}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review discusses how diabetes and hearing loss may coexist and contribute to cognitive decline, exploring mechanisms such as mitochondrial dysfunction, neuroinflammation, oxidative stress and microangiopathy. It presents no new treatment or prevention trial results and does not test whether treating either condition reduces dementia risk.

Study details

How this study scored 36/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 0 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 36 of 100.36 of 100 points earned64 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Brain Sciences)
Journal's citation record 1 / 4 Brain Sciences: journal h-index 115 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 4 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.3 citations a year over 3 year(s) since 2025
Impact for its field and year 2 / 6 Cited 2.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Paul Hinckley Delano: h-index 20 (OpenAlex, whole career)
Institution's track record 0 / 3 University of Chile: institution h-index 541 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40722262)
Free to read 2 / 2 Free to read
Total 36 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.

Related studies in Risk factors from nearby years

Also tagged “biobank”

1,084 studies in the library carry the topic tag “biobank”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,084 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Risk factors

See all studies in Risk factors →